{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:39:07Z","timestamp":1791517147072,"version":"4.3.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for patients with hematologic malignances. Haploidentical HSCT (Haplo-HSCT) is an alternative option for patients who do not have an HLA-matched donor. The use of post-transplantation high dose cyclophosphamide (PT-Cy) is commonly employed for graft-versus-host disease (GVHD) prophylaxis in haplo-HSCT. Cyclophosphamide (Cy) is an alkylating agent with antineoplastic and immunosuppressive activity, whose bioactivation requires the activity of polymorphic enzymes in the liver to produce phosphoramide mustard, which is a DNA alkylating agent. To identify polymorphisms in the genes of Cy metabolism and correlate them with post-HSCT complications [GVHD, sinusoidal obstruction syndrome (SOS), hemorrhagic cystitis (HC) and transplant-related mortality (TRM)], we designed a custom next-generation sequencing panel with Cy metabolism enzymes. We analyzed 182 patients treated with haplo-HSCT with PT-Cy from 2007 to 2019, detecting 40 variants in 11 Cy metabolism genes. Polymorphisms in CYP2B6, a major enzyme involved in Cy activation, were associated with decreased activity of this enzyme and a higher risk of Graf-versus-host disease (GVHD). Variants in other activation enzymes (CYP2A6, CYP2C8, CYP2C9, CYP2C19) lead to decreased enzyme activity and were associated with GVHD. Polymorphisms in detoxification genes such as glutathione S-transferases decreased the ability to detoxify cyclophosphamide metabolites due to lower enzyme activity, which leads to increased amounts of toxic metabolites and the development of III-IV acute GVHD. GSMT1*0 a single nucleotide polymorphism previously recognized as a risk factor for SOS was associated with a higher risk of SOS. We conclude that polymorphisms of genes involved in the metabolism of cyclophosphamide in our series are associated with severe grades of GVHD and toxicities (SOS and TRM) after haplo-HSCT and could be used to improve the clinical management of transplanted patients.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1002959","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T04:16:43Z","timestamp":1663906603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"13","author":[{"given":"Paula","family":"Mu\u00f1iz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andr\u00e9s-Zayas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Carbonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Chicano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Bail\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillen","family":"Oarbeascoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Su\u00e1rez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"G\u00f3mez Centuri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Dorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"D\u00edez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mart\u00ednez-Laperche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Bu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141979","article-title":"Cytochrome P450 oxidoreductase influences CYP2B6 activity in cyclophosphamide bioactivation","volume":"10","author":"El-Serafi","year":"2015","journal-title":"PloS One"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082562","article-title":"Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy","volume":"8","author":"Preissner","year":"2013","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500330","article-title":"Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19","volume":"5","author":"Timm","year":"2005","journal-title":"pharmacogenomics J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1097.bloodjournal8731097","article-title":"Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer","volume":"87","author":"Magni","year":"1996","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.10.1947.1947","article-title":"Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells","volume":"75","author":"Kastan","year":"1990","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11366","article-title":"Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity","volume":"92","author":"Christ","year":"2007","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.134","article-title":"Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy","volume":"10","author":"Pinto","year":"2009","journal-title":"Pharmacogenomics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.323","article-title":"Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia","volume":"23","author":"Rocha","year":"2009","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705786","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation","volume":"40","author":"Elmaagacli","year":"2007","journal-title":"Bone marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.008","article-title":"Mismatch on glutathione s-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation","volume":"20","author":"Mart\u00ednez-Bravo","year":"2014","journal-title":"Biol Blood marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2006.00624.x","article-title":"Glutathione s-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Kim","year":"2007","journal-title":"Clin Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.001","article-title":"Cytochrome P450 2B6*5 increases relapse after cyclophosphamide-containing conditioning and autologous transplantation for lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.143","article-title":"Influence of GST gene polymorphisms on busulfan pharmacokinetics in children","volume":"45","author":"Ansari","year":"2010","journal-title":"Bone marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk factors for development of and progression of hepatic veno-occlusive Disease\/Sinusoidal obstruction syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol Blood marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.9r200.x","article-title":"Veno-occlusive disease of the liver after hemopoietic cell transplantation","volume":"64","author":"Carreras","year":"2000","journal-title":"Eur J haematol"},{"key":"B18","article-title":"Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European group for blood and marrow transplantation. European group for blood and marrow transplantation chronic leukemia working party","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050347","article-title":"Genetic predictors for sinusoidal obstruction syndrome-a systematic review","volume":"11","author":"Waespe","year":"2021","journal-title":"J person Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.11.026","article-title":"Genetic susceptibility to hepatic sinusoidal obstruction syndrome in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"26","author":"Ansari","year":"2020","journal-title":"Biol Blood marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-Host disease clinical data collection: A report from the mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-Host disease: I. the 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European society for blood and marrow transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","article-title":"Pharmacogenomics of drug metabolizing enzymes and transporters: Relevance to precision medicine","volume":"14","author":"Ahmed","year":"2016","journal-title":"Genomics Proteomics Bioinf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2174\/138920009789895507","article-title":"Structure, function, regulation and polymorphism of human cytochrome P450 2A6","volume":"10","author":"Di","year":"2009","journal-title":"Curr Drug Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/fpc.0b013e32833947c2","article-title":"PharmGKB summary: very important pharmacogene information for CYP2B6","volume":"20","author":"Thorn","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Front Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.tpj.6500157","article-title":"Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation","volume":"3","author":"Xie","year":"2003","journal-title":"pharmacogenomics J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.12.708","article-title":"Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00008571-200401000-00005","article-title":"Promoter polymorphisms in glutathione-s-transferase genes affect transcription","volume":"14","author":"Guy","year":"2004","journal-title":"Pharmacogenetics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.07.010","article-title":"The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients","volume":"160","author":"Wang","year":"2015","journal-title":"Clin Immunol (Orlando Fla.)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2005.12.011","article-title":"Influence of glutathione s-transferase A1 polymorphism on the pharmacokinetics of busulfan","volume":"368","author":"Kusama","year":"2006","journal-title":"Clinica chimica Acta"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008321940","article-title":"Glutathione s-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation","volume":"48","author":"Johnson","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3778","article-title":"Glutathione s-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation","volume":"104","author":"Srivastava","year":"2004","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-Host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"New Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1042\/bj3000271","article-title":"Human glutathione s-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism","volume":"300","author":"Pemble","year":"1994","journal-title":"Biochem J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702377","article-title":"The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity","volume":"25","author":"Hassan","year":"2000","journal-title":"Bone marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158890","article-title":"CYP2B6rs2279343 is associated with improved survival of pediatric rhabdomyosarcoma treated with cyclophosphamide","volume":"11","author":"Labib","year":"2016","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2009.11","article-title":"A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo","volume":"9","author":"Al Koudsi","year":"2009","journal-title":"pharmacogenomics J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2133\/dmpk.dmpk-12-rv-085","article-title":"Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs","volume":"28","author":"Hirota","year":"2013","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1002959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T04:16:47Z","timestamp":1663906607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1002959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2022.1002959"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1002959","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"1002959"}}